# A Multi-center, Single-arm, Prospective Non-interventional Study to Investigate the Safety Profiles and Effectiveness of Liposomal Irinotecan (ONIVYDE®) in Combination with 5-fluorouracil (5-FU) and Leucovorin (LV) in Chinese Patients with Metastatic Pancreatic Cancer As Approval Condition (SEOPAC)

> **NCT06688240** · — · NOT_YET_RECRUITING · sponsor: **Servier (Tianjin) Pharmaceutical Co. LTD.** · enrollment: 120 (estimated)

## Conditions studied

- Metastatic Pancreatic Cancer

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06688240
- **Lead sponsor:** Servier (Tianjin) Pharmaceutical Co. LTD.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-11
- **Primary completion:** 2027-07
- **Final completion:** 2027-07
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2024-11-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06688240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06688240, "A Multi-center, Single-arm, Prospective Non-interventional Study to Investigate the Safety Profiles and Effectiveness of Liposomal Irinotecan (ONIVYDE®) in Combination with 5-fluorouracil (5-FU) and Leucovorin (LV) in Chinese Patients with Metastatic Pancreatic Cancer As Approval Condition (SEOPAC)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06688240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*